Hemogenyx Pharmaceuticals PLC Announces Notice of AGM

Rhea-AI Summary

Hemogenyx Pharmaceuticals (OTC:HOPHF, LSE:HEMO) has posted its Annual Report and Accounts for the year ended 31 December 2025, together with the Notice of Annual General Meeting (AGM) and Form of Proxy, to shareholders.

The AGM will be held on 30 June 2026 at 2:00 pm BST at One Heddon Street, London, W1B 4BD, and these documents will also be available on the company’s investor relations website.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Posting of Annual Report & Notice of Annual General Meeting

LONDON, UK / ACCESS Newswire / June 5, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2025, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and will shortly be available on the Company's website at https://hemogenyx.com/investors/annual-half-year-reports/.

The AGM is to be held on 30 June 2026 at 2.00 pm BST at One Heddon Street, London, W1B 4BD.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
AlbR Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals plc

View the original press release on ACCESS Newswire

FAQ

When is the Hemogenyx Pharmaceuticals (HOPHF) 2026 AGM and where will it be held?

The Hemogenyx Pharmaceuticals 2026 AGM is scheduled for 30 June 2026 at 2:00 pm BST. According to the company, it will take place at One Heddon Street, London, W1B 4BD, providing shareholders a formal venue to vote on AGM resolutions.

What documents has Hemogenyx Pharmaceuticals (HOPHF) posted ahead of the 2026 AGM?

Hemogenyx Pharmaceuticals has posted its Annual Report and Accounts for the year ended 31 December 2025, along with the AGM Notice and Form of Proxy. According to the company, these materials support shareholder review of performance and governance before voting at the 2026 AGM.

Where can investors access the Hemogenyx Pharmaceuticals 2025 Annual Report online?

Investors can access the Hemogenyx Pharmaceuticals 2025 Annual Report on the company’s investor relations website. According to the company, it will be available under the annual and half-year reports section, allowing shareholders to review detailed information ahead of the 2026 AGM.

What is Hemogenyx Pharmaceuticals’ business focus as a clinical-stage company?

Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical group developing new medicines for blood and autoimmune diseases. According to the company, it is advancing several distinct and complementary product candidates and platform technologies designed to support novel therapy development in hematology and immunology.

On which stock exchanges is Hemogenyx Pharmaceuticals (HOPHF) listed?

Hemogenyx Pharmaceuticals is publicly traded on the London Stock Exchange under ticker HEMO, and also trades over-the-counter as HOPHF. According to the company, it is headquartered in London with operating subsidiaries based in New York City in the United States.

How can shareholders contact Hemogenyx Pharmaceuticals regarding AGM or investor queries?

Shareholders can contact Hemogenyx Pharmaceuticals via its listed corporate email addresses and advisors. According to the company, the primary contact is the headquarters email, with additional contacts at SP Angel Corporate Finance and AlbR Capital Limited for corporate finance and brokerage-related enquiries.